(Q33640993)

28 July 2017

1 reference

title

HIV disease treatment in the era of HAART. (English)

1 reference

28 July 2017

Bonfanti P

1

1 reference

28 July 2017

Capetti A

series ordinal

2

1 reference

28 July 2017

Rizzardini G

series ordinal

3

1 reference

28 July 2017

publication date

1 March 1999

1 reference

Biomedicine and Pharmacotherapy

28 July 2017

published in

1 reference

28 July 2017

volume

53

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

93-105

1 reference

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

HIV viral load markers in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Nelfinavir. A review of its therapeutic efficacy in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Indinavir-associated lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

HIV infection: a model chronic illness for studying wasting diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

New strategies to combat HIV drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The era of adherence to HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980066-3

7 January 2021

10.1016/S0753-3322(99)80066-3

Identifiers

DOI

1 reference

28 July 2017

1 reference